Affordable Access

deepdyve-link deepdyve-link
Publisher Website

AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.

Authors
Type
Published Article
Journal
Psychopharmacology
Publication Date
Volume
215
Issue
1
Pages
149–163
Identifiers
DOI: 10.1007/s00213-010-2124-0
PMID: 21181124
Source
Medline
License
Unknown

Abstract

These preclinical data suggest that AVE1625 may be useful to treat the cognitive deficits in schizophrenia and as a co-treatment with currently available antipsychotics. In addition, an improved side-effect profile was seen, with potential to ameliorate the EPS and weight gain issues with currently available treatments.

Statistics

Seen <100 times